| 4.665 0.13 (2.87%) | 07-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.27 | 1-year : | 6.87 |
| Resists | First : | 5.37 | Second : | 5.88 |
| Pivot price | 5.05  |
|||
| Supports | First : | 4.53 | Second : | 3.77 |
| MAs | MA(5) : | 4.73 |
MA(20) : | 5.13 |
| MA(100) : | 4.31 |
MA(250) : | 4.13 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 8 |
D(3) : | 9.2 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 5.88 | Low : | 2.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATHE ] has closed above bottom band by 26.7%. Bollinger Bands are 30.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.75 - 4.78 | 4.78 - 4.81 |
| Low: | 4.47 - 4.51 | 4.51 - 4.54 |
| Close: | 4.7 - 4.75 | 4.75 - 4.8 |
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Mon, 27 Jul 2026
ATHE|Alterity Therapeutics Ltd|Price:4.540|Chg%:-0.155 - TradingKey
Sun, 26 Jul 2026
Alterity Therapeutics Ltd (ATHE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sun, 26 Jul 2026
PRNAF SEC Filings - ALTERITY THERAPEUTICS LTD 10-K, 10-Q, 8-K Forms - Stock Titan
Sun, 26 Jul 2026
Alterity Therapeutics Ltd (ATHE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sat, 25 Jul 2026
Alterity Therapeutics Ltd (ATHE) Cash Flow - TradingKey
Sat, 25 Jul 2026
ATHE|Alterity Therapeutics Ltd|Price:4.540|Chg%:-0.155 - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 18 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 54 (K) |
| EPS | -0.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 104.41 |
| Profit Margin | -219.9 % |
| Operating Margin | -372.6 % |
| Return on Assets (ttm) | -32.6 % |
| Return on Equity (ttm) | -47.1 % |
| Qtrly Rev. Growth | 74.5 % |
| Gross Profit (p.s.) | 0.35 |
| Sales Per Share | 0.36 |
| EBITDA (p.s.) | -0.97 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -8.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.04 |
| Price to Sales | 12.96 |
| Price to Cash Flow | -6.29 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|